Survival Outcomes of Patients with Mantle Cell Lymphoma: A Retrospective, 15-Year, Real-Life Study

被引:4
作者
Cencini, Emanuele [1 ]
Calomino, Natale [2 ]
Franceschini, Marta [1 ]
Dragomir, Andreea [1 ]
Fredducci, Sara [1 ]
Vangone, Beatrice Esposito [1 ]
Navei, Giulia Lucco [1 ]
Fabbri, Alberto [1 ]
Bocchia, Monica [1 ]
机构
[1] Univ Siena, Unit Hematol, Azienda Ospedaliera Univ Senese, I-53100 Siena, Italy
[2] Univ Siena, Dept Med Surg & Neurosci, Unit Gen Surg & Surg Oncol, I-53100 Siena, Italy
关键词
mantle cell lymphoma; chemoimmunotherapy; target therapy; survival; TERM-FOLLOW-UP; OLDER PATIENTS; BENDAMUSTINE; RITUXIMAB; TRANSPLANTATION; CYTARABINE; IBRUTINIB; THERAPY; UPDATE; TRIAL;
D O I
10.3390/hematolrep16010006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mantle cell lymphoma (MCL) prognosis has significantly improved in recent years; however, the possible survival benefit of new treatment options should be evaluated outside of clinical trials. We investigated 73 consecutive MCL patients managed from 2006 to 2020. For younger patients <65 years old, the median PFS was 72 months and we reported a 2-year, 5-year, and 10-year PFS of 73%, 62%, and 41%; median OS was not reached and we reported a 2-year, 5-year, and 10-year OS of 88%, 82%, and 66%. For patients aged 75 years or older, the median PFS was 36 months and we reported a 2-year, 5-year, and 10-year PFS of 52%, 37%, and 37%; median OS was not reached and we reported a 2-year, 5-year, and 10-year OS of 72%, 55%, and 55%. The median PFS was significantly reduced for patients treated between 2006 and 2010 compared to patients treated between 2011 and 2015 (p = 0.04). Interestingly, there was a trend towards improved OS for patients treated between 2016 and 2020 compared to between 2006 and 2010 and between 2011 and 2015 (5-year OS was 91%, 44%, and 33%). These findings could be due to the introduction of BR as a first-line regimen for elderly patients and to the introduction of ibrutinib as a second-line regimen.
引用
收藏
页码:50 / 62
页数:13
相关论文
共 47 条
[1]   Mantle cell lymphoma treatment options for elderly/unfit patients: A systematic review [J].
Alnassfan, Tahera ;
Cox-Pridmore, Megan J. ;
Taktak, Azzam ;
Till, Kathleen J. .
EJHAEM, 2022, 3 (01) :276-290
[2]   Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma [J].
Bega, Giulia ;
Olivieri, Jacopo ;
Riva, Marcello ;
Scapinello, Greta ;
Paolini, Rossella ;
Finotto, Silvia ;
Sartori, Roberto ;
Lucchini, Elisa ;
Guandalini, Gianmarco ;
Facchinelli, Davide ;
Tisi, Maria Chiara ;
Basso, Marco ;
Ballotta, Laura ;
Piazza, Francesco ;
Ferrarini, Isacco ;
Visco, Carlo .
CANCERS, 2021, 13 (23)
[3]   The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study [J].
Cencini, Emanuele ;
Sicuranza, Anna ;
Fabbri, Alberto ;
Marzano, Cristina ;
Pacelli, Paola ;
Caroni, Federico ;
Raspadori, Donatella ;
Bocchia, Monica .
LEUKEMIA & LYMPHOMA, 2023, 64 (10) :1634-1642
[4]   Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab [J].
Cencini, Emanuele ;
Sicuranza, Anna ;
Fabbri, Alberto ;
Ferrigno, Ilaria ;
Rigacci, Luigi ;
Cox, Maria C. ;
Raspadori, Donatella ;
Bocchia, Monica .
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (02) :223-231
[5]   Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis [J].
Di, Mengyang ;
Long, Jessica B. ;
Kothari, Shalin K. ;
Sethi, Tarsheen ;
Zeidan, Amer M. ;
Podoltsev, Nikolai A. ;
Shallis, Rory M. ;
Wang, Rong ;
Ma, Xiaome ;
Huntington, Scott F. .
HAEMATOLOGICA, 2023, 108 (08) :2218-2223
[6]  
Dreyling M, 2017, ANN ONCOL, V28, P62, DOI [10.1093/annonc/mdx223, 10.1093/annonc/mdx289]
[7]   ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma [J].
Dreyling, M. ;
Thieblemont, C. ;
Gallamini, A. ;
Arcaini, L. ;
Campo, E. ;
Hermine, O. ;
Kluin-Nelemans, J. C. ;
Ladetto, M. ;
Le Gouill, S. ;
Iannitto, E. ;
Pileri, S. ;
Rodriguez, J. ;
Schmitz, N. ;
Wotherspoon, A. ;
Zinzani, P. ;
Zucca, E. .
ANNALS OF ONCOLOGY, 2013, 24 (04) :857-877
[8]   Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up [J].
Dreyling, Martin ;
Goy, Andre ;
Hess, Georg ;
Kahl, Brad S. ;
Hernandez-Rivas, Jose-Angel ;
Schuier, Natasha ;
Qi, Keqin ;
Deshpande, Sanjay ;
Zhu, Angeline ;
Parisi, Lori ;
Wang, Michael L. .
HEMASPHERE, 2022, 6 (05)
[9]   15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau [J].
Eskelund, Christian W. ;
Kolstad, Arne ;
Jerkeman, Mats ;
Raty, Riikka ;
Laurell, Anna ;
Eloranta, Sandra ;
Smedby, Karin E. ;
Husby, Simon ;
Pedersen, Lone B. ;
Andersen, Niels S. ;
Eriksson, Mikael ;
Kimby, Eva ;
Bentzen, Hans ;
Kuittinen, Outi ;
Lauritzsen, Grete F. ;
Nilsson-Ehle, Herman ;
Ralfkiaer, Elisabeth ;
Ehinger, Mats ;
Sundstrom, Christer ;
Delabie, Jan ;
Karjalainen-Lindsberg, Marja-Liisa ;
Workman, Christopher T. ;
Garde, Christian ;
Elonen, Erkki ;
Brown, Peter ;
Gronbaek, Kirsten ;
Geisler, Christian H. .
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (03) :410-418
[10]   Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma [J].
Fisher, Richard I. ;
Bernstein, Steven H. ;
Kahl, Brad S. ;
Djulbegovic, Benjamin ;
Robertson, Michael J. ;
de Vos, Sven ;
Epner, Elliot ;
Krishnan, Amrita ;
Leonard, John P. ;
Lonial, Sagar ;
Stadtmauer, Edward A. ;
O'Connor, Owen A. ;
Shi, Hongliang ;
Boral, Anthony L. ;
Goy, Andre .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) :4867-4874